Supernus Pharmaceuticals, Inc. (SUPN): Debt to Book Capitalization Ratio

Stable demand for CNS therapies provides Supernus Pharmaceuticals (SUPN) with a predictable cash flow. However, the loss of exclusivity for Trokendi XR and challenges regarding the approval of a Parkinson's treatment pump are creating financial pressure, and the metric stands at 0.04. The business relies on third-party drug manufacturing to focus on R&D. This chart of the market price on the GURU.Markets platform visualizes the price action of this neuropharmaceutical asset.

In the neurology pharmaceutical sector, the debt-to-equity ratio is critical, as it allows for an assessment of financial leverage and the risk of net asset loss. By analyzing the total debt relative to market capitalization, an investor determines the ability of Supernus Pharmaceuticals (SUPN) to withstand patent risks and generic competition, evaluating the overall stability of the company's balance sheet structure.